# Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

> **NCT02537600** · PHASE2 · COMPLETED · sponsor: **Center Eugene Marquis** · enrollment: 43 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Cobimetinib + Vemurafenib combination treatment

## Key facts

- **NCT ID:** NCT02537600
- **Lead sponsor:** Center Eugene Marquis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2019-11-06
- **Final completion:** 2019-11-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02537600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02537600, "Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02537600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*